Posted by 
Lymphoma is the most common blood cancer, and CLL/SLL and FL are common types of indolent non-Hodgkin lymphomas (iNHL). Many patients will eventually relapse or develop refractory disease, patients living with CLL/SLL FL are in need of additional treatment options, and new therapies such as Copiktra are crucial because each patient’s treatment journey is unique.
Copiktra is an oral inhibitor of phosphoinositide 3-kinase (PI3K), dual inhibitor of PI3K-delta and PI3K-gamma. Copiktra is for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies. It can also be used for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.
Copiktra is an important addition to the evolving treatment paradigm for patients with CLL/SLL and FL Copiktra is a significant addition to physicians’ treatment armamentarium. The use of Copiktra is also associated with adverse reactions which may require dose reduction, treatment delay or discontinuation of Copiktra.
Common adverse reactons of Copiktra are infections, diarrhea or colitis, cutaneous reactions, pneumonitis, hepatotoxicity, neutropenia, embryo-fetal toxicity, rash, fatigue, pyrexia, cough, nausea, upper respiratory infection, pneumonia, musculoskeletal pain, and anemia.